What Does the Published Research Say About Pemvidutide?

What This Article Covers

This article summarizes published research on Pemvidutide for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.

Pemvidutide is identified in the available evidence set as a dual glucagon-like peptide-1 (GLP-1)/glucagon receptor agonist. The evidence set contains bibliographic records for randomized human studies in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), along with reviews, meta-analyses, a modeling abstract, and broader metabolic-research publications.

This is a scope-limited assessment of that evidence set. Only one citation—an MASLD randomized trial—has a claim-level synthesis describing its population, design, and liver-fat endpoint [pubmed:39002641]. The evidence set identifies additional randomized and phase 2b clinical reports by title, but it does not supply their numerical outcomes, adverse-event frequencies, sample characteristics, or full-text findings [pubmed:41113119; pubmed:41237796; pubmed:41352959]. Those reports are therefore acknowledged as primary clinical literature but are not used here to estimate efficacy or safety.

The synthesis guidance characterizes the available material as review-heavy relative to the primary human evidence and recommends anchoring conclusions in primary studies. The bibliographic list does contain several apparent clinical reports, but the evidence set does not establish whether all represent independent trials, overlapping reports, or companion publications. They should not be counted as separate independent studies without full-text reconciliation.

Bottom Line

Published research in the evidence set shows that pemvidutide has reached randomized human testing in defined metabolic liver-disease populations. One randomized, double-blind, placebo-controlled MASLD study specifically assessed liver fat content [pubmed:39002641]. Additional records identify a 24-week randomized MASLD trial and phase 2b MASH reports [pubmed:41113119; pubmed:41237796; pubmed:41352959].

What cannot be concluded from the supplied synthesis is equally important. It does not report effect sizes, statistical estimates, responder rates, adverse-event frequencies, or sufficient comparative results from these trials. The evidence set therefore supports a conclusion about the existence and scope of human research—not a quantitative conclusion about efficacy, safety, or clinical usefulness.

What Was Tested in Humans?

Randomized MASLD study with claim-level synthesis

The most directly summarized human evidence is a randomized, double-blind, placebo-controlled study of pemvidutide in people with MASLD. Its stated purpose was to assess effects on liver fat content [pubmed:39002641].

This establishes that pemvidutide was evaluated under controlled clinical conditions in a defined liver-disease population. The supplied synthesis does not include the study’s numerical results, effect estimates, sample details, or adverse-event frequencies. Consequently, the citation supports statements about the study design and endpoint but not a quantitative judgment about treatment effect or safety.

Any interpretation should remain tied to the studied MASLD population and liver-fat endpoint. The study cannot, from the information supplied, establish effects in other populations, disease settings, or endpoints.

Additional primary clinical reports identified in the evidence set

The evidence set also contains the following records whose titles identify them as primary clinical reports rather than review articles:

• A randomized, controlled clinical trial evaluating 24 weeks of pemvidutide in MASLD [pubmed:41113119].
• A multicentre, randomized, double-blind, phase 2b study reporting 24-week results in MASH [pubmed:41237796].
• A publication titled as a phase 2b trial of pemvidutide in MASH [pubmed:41352959].
• A Crossref record with the same phase 2b MASH title, which may correspond to one of the PubMed-indexed reports rather than a separate trial [crossref:10.1016/s0140-6736(25)02304-9].
• A conference abstract concerning plasma lipidomic profiling after pemvidutide exposure in participants with overweight or obesity [crossref:10.1016/s0168-8278(24)01588-5].

These citations correct the impression that the evidence set contains only one human trial record. However, their outcome data were not provided in the claim-level synthesis. This article therefore does not infer their results, combine them quantitatively, or treat each record as evidence from an independent participant cohort.

What Did Animal and Mechanistic Studies Show?

The available evidence set should be interpreted carefully when it includes animal, cellular, formulation, or mechanistic findings. Those findings can explain why researchers study the compound, but they should not be presented as established human outcomes.

How the Evidence Fits Together

The practical reading for Pemvidutide is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.

What Is Not Established

• Broad human efficacy for Pemvidutide is not established by this article.
• Animal, cellular, or review-level findings should not be converted into human-use claims.
• Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.

Research-Use Boundary

This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.

Selected Sources

• Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. PubMed: 39002641.
• Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. PubMed: 41113119.
• Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. PubMed: 41237796.
• The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial. PubMed: 41352959.
• The dual GLP-1–glucagon agonist pemvidutide in MASH: a phase 2b trial. Crossref: 10.1016/S0140-6736(25)02304-902304-9).
• Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials. PubMed: 41879841.
• Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis. PubMed: 42529769.
• Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. PubMed: 40081498.
• Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article. PubMed: 39676791.
• Emerging concepts in obesity management: focus on glucagon receptor agonist combinations. PubMed: 40734920.
• Current priorities in research on metabolic-associated fatty liver disease based on the results of EASL—2024. PubMed: 40063921.
• Plasma lipidomic profiling of subjects with overweight or obesity following treatment with pemvidutide. Crossref: 10.1016/S0168-8278(24)01588-501588-5).
• Pemvidutide improves MASH activity and fibrosis in a clinical quantitative systems pharmacology model. Crossref: 10.1016/S0168-8278(24)01560-501560-5).

Related KRL Resources

• Research Compound Catalog
• Technical Products
• FAQ